8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)        November 7, 2007

MGT Capital Investments, Inc.

(Exact name of registrant as specified in its charter)

Delaware	0-26886	13-4148725
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

Kensington Centre, 66 Hammersmith Road, London, United
Kingdom	W14 8UD
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code       011-44-20-7605-7950

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01.  Other Events

On November 7, 2007, Medicsight PLC (LSE: MDST.L), a subsidiary of the Company, released the attached Interim Results for the nine months ended September 30, 2007 pursuant to the AIM market requirements of the London Stock Exchange.

Item 9.01.  Financial Statements and Exhibits

The press release is filed as Exhibit 1 to this report on Form 8-K and is incorporated herein by reference.

(d)	Exhibit .
1	Interim Results of Medicsight PLC

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	MGT CAPITAL INVESTMENTS, INC.
	By:	/s/ TIM PATERSON-BROWN
	Tim Paterson-Brown
	Chairman and Chief Executive Officer
Date:  November 7, 2007

2

EX-1

Exhibit 1

Press Release

Medicsight PLC

(“Medicsight” or “the Company”)

Third Quarter Summary Trading Statement

Medicsight PLC (AIM:MDST), industry leader in the development of Computer-Aided Detection (CAD) and image analysis software which assists in the early detection and diagnosis of disease, is pleased to announce summary Interim Results for the quarter ended 30 September 2007.

Highlights

•First commercial bookings

•Regulatory approval granted in Australia for ColonCAD™

David Sumner, Chief Executive of Medicsight PLC, commented: “I am delighted to announce that the Company’s first revenue bookings have taken place this quarter. This is an important commercial milestone for the Company and paves the way for anticipated profitability in 2008. In addition our contract pipeline also continues to grow and regulatory approvals continue as planned, including the initial regulatory approval for our ColonCAD™ product in Australia. In relation to future product delivery, the development group is making good progress and is on schedule to deliver against the revised product roadmap.

“The most important news item however for this quarter is the recent announcement from The American College of Radiology Imaging Network (ACRIN), a national cancer research organization sponsored and funded by the US National Cancer Institute, in relation to the ACRIN 6664 study. This large multi-centre study demonstrates that CT Colonography is as sensitive as Optical Colonoscopy when screening for colorectal polyps with a diameter in excess of 1 cm. We believe that this landmark clinical study now provides the data required to enable CT Colonography to be included in the major screening guidelines for colorectal cancer in the USA. This also makes the reimbursement landscape look very encouraging for CT Colonography in the world’s largest medical imaging market.”

Summary Financial Data

For the three months to 30 September 2007 net revenue to external customers was £6,000 (2006: nil) with an operating loss before interest and tax of £1,883,000 (2006: £551,000). For the nine months to 30 September 2007 net revenue to external customers was £6,000 (2006: nil) with an operating loss before interest and tax of £5,449,000 (2006: £3,706,000). Reflecting the funds raised in the initial public offering in June this year, the Group’s total assets at 30 September 2007 were £27,412,000 (30 September 2006: £1,169,000).

For further information:

Medicsight PLC
David Sumner	Tel: +44 (0)20 7605 7950
	www.medicsight.com
Collins Stewart Europe Limited
Tim Mickley	Tel: +44 (0)20 7523 8350
Jonny Sloan	Tel: +44 (0)20 7523 8302

Media enquiries:

Abchurch
Ashley Tapp	Tel: +44 (0) 20 7398 7700
ashley.tapp@abchurch-group.com
Stephanie Cuthbert	Tel: +44 (0) 20 7398 7700
stephanie.cuthbert@abchurch-group.com	www.abchurch-group.com